Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells
Brian H. Shim, Q. Henry Zhao, Jack A. Queenan, Blake E. Smith, Michael E. Birnbaum, David R. Liu · 2026
Read Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells by Brian H. Shim, Q. Henry Zhao, Jack A. Queenan, Blake E. Smith, Michael E. Birnbaum, David R. Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13426065.txt.
Description
Shim and co-authors engineered virus-like particles decorated with peptide-MHC complexes. Those complexes are the display molecules that show T cells their targets. The goal was to find and upgrade the rare tumor-specific T cells inside a patient's repertoire. Tumor-infiltrating lymphocyte therapy is limited by how few of those cells exist, and by how dysfunctional they often are.
The particles selectively prime and expand only the T cells matching the displayed tumor peptide. They ignore bystander cells entirely. They also deliver base editors, precision gene-editing tools. Those editors enhance the killing power of the selected tumor-specific cells. In the reported experiments, the platform armed mixed lymphocyte populations with stronger anti-tumor cytotoxicity. The authors present the system as a way to improve lymphocyte therapy. It avoids the off-target engineering risks of treating all T cells at once.
Catalog record
| CREATOR | Brian H. Shim, Q. Henry Zhao, Jack A. Queenan, Blake E. Smith, Michael E. Birnbaum, David R. Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |